This post is also available in:
עברית (Hebrew)
Significant loss of blood can cause death in a matter of minutes. On the battlefield, where a dangerous environment is coupled with being far away from a hospital, first aid that can stop the bleeding effectively can save lives.
TraumaGel, a type of advanced first aid product developed by Biotechnology firm Cresilon Inc. and designed to address severe bleeding and injuries was recently approved by the FDA.
This product, specifically designed with combatants in mind, is used for rapid control of severe bleeding, particularly in trauma situations. It is made to be applied directly to the wound to help stop bleeding and promote clotting and can be used both by medical professionals and by novices as it conveniently comes inside a pre-filled syringe for easy application.
Made with a combination of algae and fungi compounds, the gel contains hemostatic agents—substances that promote blood clotting by accelerating the body’s natural clotting process. The gel works quickly, helping to reduce the risk of significant blood loss.
By effectively managing severe bleeding, TraumaGel can be crucial in emergency situations, potentially saving lives by controlling blood loss until more advanced medical care can be provided. According to the company’s press release, “The FDA clearance for TRAUMAGEL is a monumental milestone for Cresilon and brings us another step forward in our mission to save lives and transform the standard of care in emergency medicine. Our proprietary hemostatic gel technology is a game-changer and unlike any other hemostatic agent currently being used.”
In addition to its military applications, the substance will also be made available to government health agencies, medical professionals, and emergency medical services. Traumagel is expected to be launched by Cresilon to the US market by late 2024.
